Mild cognitive impairment (MCI) and incipient Alzheimer disease - A role for biomarkers in CSF

Research and Practice in Alzheimer's Disease

Volumn 10, Issue , 2005, Pages 97-100

  Andreasen, Niels ^a   Blennow, K ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

AD; Biomarkers; CSF; MCI

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PROTEIN TAU P; PROTEIN TAU T; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; NERVE DEGENERATION; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 32044458882     PISSN: 12848360     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (5)

1. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003 Oct;2(10):605-13.
2. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999 Sep 24;273(1):5-8.
3. Andreasen N, Minthon L, Davidsson P, Vanderstichele H, Vanmechelen E, Winblad B, Blennow K. Evaluation of CSF-tau and CSF-Ab42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch Neurol. 2001 Mar;58(3):373-9.
4. Hampel H, Buerger K, Zinkowski R, Goernitz A, Teipel SJ, Andreasen N, Sjogren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Möller HJ, Davies P, Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer's disease - a comparative CSF study. Arch Gen Psychiatry, 2004 Jan;61(1):95-102.
5. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Longitudinal studies of cerebrospinal fluid biochemistry in patients with mild cognitive impairment. Acta Neurol Scand 2003 Feb;107 Suppl 179:47-51